Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial

[1]  Adnan I. Qureshi,et al.  Guidelines for the Early Management of Adults With Ischemic Stroke , 2007 .

[2]  M E Moseley,et al.  Evolution of cerebral infarct volume assessed by diffusion-weighted magnetic resonance imaging. , 2001, Archives of neurology.

[3]  P. Schellinger,et al.  Two Tales: Hemorrhagic Transformation but Not Parenchymal Hemorrhage After Thrombolysis Is Related to Severity and Duration of Ischemia: MRI Study of Acute Stroke Patients Treated With Intravenous Tissue Plasminogen Activator Within 6 Hours , 2007, Stroke.

[4]  A. Villringer,et al.  Effect of Intravenous Thrombolysis on MRI Parameters and Functional Outcome in Acute Stroke <6 Hours , 2002, Stroke.

[5]  C. Weiller,et al.  Outcome and Symptomatic Bleeding Complications of Intravenous Thrombolysis Within 6 Hours in MRI-Selected Stroke Patients: Comparison of a German Multicenter Study With the Pooled Data of ATLANTIS, ECASS, and NINDS tPA Trials , 2006, Stroke.

[6]  S M Davis,et al.  Prediction of stroke outcome with echoplanar perfusion- and diffusion-weighted MRI , 1998, Neurology.

[7]  R. Higashida,et al.  Intra-arterial Prourokinase for Acute Ischemic Stroke: The PROACT II Study: A Randomized Controlled Trial , 1999 .

[8]  L. Symon.  Recovery of brain function after ischaemia. , 1987, Acta neurochirurgica. Supplementum.

[9]  P. Sandercock,et al.  Third International Stroke Trial , 2006, International journal of stroke : official journal of the International Stroke Society.

[10]  G. Donnan,et al.  Selection of thrombolytic therapy beyond 3 h using magnetic resonance imaging , 2005, Current opinion in neurology.

[11]  G. Donnan,et al.  Proof-of-Principle Phase II MRI Studies in Stroke: Sample Size Estimates From Dichotomous and Continuous Data , 2006, Stroke.

[12]  B. Rosen,et al.  High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: Mathematical approach and statistical analysis , 1996, Magnetic resonance in medicine.

[13]  Steven Warach,et al.  Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): Evidence of Safety and Efficacy 3 to 9 Hours After Stroke Onset , 2006, Stroke.

[14]  R J Seitz,et al.  Diffusion- and perfusion-weighted MRI. The DWI/PWI mismatch region in acute stroke. , 1999, Stroke.

[15]  P Sandercock,et al.  Magnetic resonance perfusion diffusion mismatch and thrombolysis in acute ischaemic stroke: a systematic review of the evidence to date , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[16]  S. Warach,et al.  The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): A Phase II MRI-Based 9-Hour Window Acute Stroke Thrombolysis Trial With Intravenous Desmoteplase , 2005, Stroke.

[17]  P. Barber,et al.  The Use of PWI and DWI Measures in the Design of “Proof‐of‐Concept” Stroke Trials , 2004, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[18]  W. Hacke,et al.  Monitoring intravenous recombinant tissue plasminogen activator thrombolysis for acute ischemic stroke with diffusion and perfusion MRI. , 2000, Stroke.

[19]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[20]  C. Weiller,et al.  Type and extent of hemispheric brain infarctions and clinical outcome in early and delayed middle cerebral artery recanalization , 1992, Neurology.

[21]  Stephen Rose,et al.  Diffusion‐ and perfusion‐weighted MRI response to thrombolysis in stroke , 2002, Annals of neurology.

[22]  B. Siewert,et al.  Acute human stroke studied by whole brain echo planar diffusion‐weighted magnetic resonance imaging , 1995, Annals of neurology.

[23]  S M Davis,et al.  Pathophysiological topography of acute ischemia by combined diffusion-weighted and perfusion MRI. , 1999, Stroke.

[24]  Werner Hacke,et al.  MRI versus CT-based thrombolysis treatment within and beyond the 3 h time window after stroke onset: a cohort study , 2006, The Lancet Neurology.

[25]  T. Neumann-Haefelin,et al.  MRI-Based and CT-Based Thrombolytic Therapy in Acute Stroke Within and Beyond Established Time Windows: An Analysis of 1210 Patients , 2007, Stroke.

[26]  J. Arenillas,et al.  Time Course of Tissue Plasminogen Activator–Induced Recanalization in Acute Cardioembolic Stroke: A Case-Control Study , 2001, Stroke.

[27]  W Hacke,et al.  Stroke magnetic resonance imaging within 6 hours after onset of hyperacute cerebral ischemia , 2001, Annals of neurology.

[28]  Scott Hamilton,et al.  Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials , 2004, The Lancet.

[29]  S. Warach.  New imaging strategies for patient selection for thrombolytic and neuroprotective therapies , 2001, Neurology.

[30]  P. Sandercock,et al.  Comparison of 10 Different Magnetic Resonance Perfusion Imaging Processing Methods in Acute Ischemic Stroke: Effect on Lesion Size, Proportion of Patients With Diffusion/Perfusion Mismatch, Clinical Scores, and Radiologic Outcomes , 2007, Stroke.

[31]  G. Donnan,et al.  Perfusion thresholds in acute stroke thrombolysis. , 2003, Stroke.

[32]  Werner Hacke,et al.  Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study , 2007, The Lancet.

[33]  Scott Hamilton,et al.  Magnetic resonance imaging profiles predict clinical response to early reperfusion: The diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study , 2006, Annals of neurology.

[34]  M. Kaste,et al.  Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) , 1995, JAMA.

[35]  P. Barber,et al.  Refining the Perfusion—Diffusion Mismatch Hypothesis , 2005, Stroke.